Pembrolizumab (Keytruda, MSD) as monotherapy is indicated 'for the treatment of resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price is £2,630.00 per 100 mg vial (excluding VAT; BNF online accessed March 2026).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on MSD's webpage on responsibility.